ClinVar Miner

Submissions for variant NM_006231.4(POLE):c.4237G>A (p.Glu1413Lys)

gnomAD frequency: 0.00016  dbSNP: rs372901803
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001079665 SCV000289371 likely benign Colorectal cancer, susceptibility to, 12 2021-12-17 criteria provided, single submitter clinical testing
GeneDx RCV000679632 SCV000569654 likely benign not provided 2021-06-14 criteria provided, single submitter clinical testing
PreventionGenetics,PreventionGenetics RCV000679632 SCV000806776 uncertain significance not provided 2017-01-10 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000487363 SCV000920078 likely benign not specified 2018-12-14 criteria provided, single submitter clinical testing Variant summary: POLE c.4237G>A (p.Glu1413Lys) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00031 in 277202 control chromosomes (gnomAD). The observed variant frequency is approximately 21.59 fold of the estimated maximal expected allele frequency for a pathogenic variant in POLE causing Colorectal Cancer phenotype (1.4e-05), strongly suggesting that the variant is benign. c.4237G>A has been reported in the literature in individual(s) affected with advanced cancer without strong evidence for causality; the variant was classified by the authors of the study as uncertain significance (Mandelker_2017). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as likely benign (2x) and once as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000679632 SCV001134724 benign not provided 2019-07-08 criteria provided, single submitter clinical testing
Genetic Services Laboratory,University of Chicago RCV000487363 SCV002066979 uncertain significance not specified 2019-12-02 criteria provided, single submitter clinical testing
Sema4,Sema4 RCV002257582 SCV002536839 likely benign Hereditary cancer-predisposing syndrome 2021-03-29 criteria provided, single submitter curation
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000679632 SCV001549972 uncertain significance not provided no assertion criteria provided clinical testing The POLE p.Glu1413Lys variant was identified in 1 of 2080 proband chromosomes (frequency: 0.0005) from individuals or families with unspecified cancer (Mandelker 2017). The variant was also identified in dbSNP (ID: rs372901803) as "With Likely benign allele", in ClinVar (classified as likely benign by Invitae and GeneDx; as uncertain significance by Prevention Genetics). The variant was identified in control databases in 85 of 277202 chromosomes at a frequency of 0.0003 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 1 of 6466 chromosomes (freq: 0.0002), Latino in 44 of 34418 chromosomes (freq: 0.001), European Non-Finnish in 6 of 126690 chromosomes (freq: 0.00005), Ashkenazi Jewish in 34 of 10152 chromosomes (freq: 0.003); it was not observed in the African, East Asian, Finnish, and South Asian populations. The p.Glu1413 residue is conserved in mammals but not in more distantly related organisms however four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.